Revance Therapeutics Inc (RVNC)
3.07
-0.01
(-0.32%)
USD |
NASDAQ |
Dec 23, 16:00
3.07
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Cash from Financing (Quarterly): -6.087M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Recursion Pharmaceuticals Inc | 16.46M |
| Regeneron Pharmaceuticals Inc | -634.00M |
| Ligand Pharmaceuticals Inc | 55.08M |
| MEI Pharma Inc | -- |
| Cellectar Biosciences Inc | 17.56M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -41.09M |
| Cash from Investing (Quarterly) | 23.29M |
| Free Cash Flow | -194.91M |
| Free Cash Flow Per Share (Quarterly) | -0.3949 |
| Free Cash Flow to Equity (Quarterly) | -41.76M |
| Free Cash Flow to Firm (Quarterly) | -36.88M |
| Free Cash Flow Yield | -65.63% |